Anondita Medicare H1 EBITDA rises 70% as margin reaches 45.28%
Key highlights
- Anondita Medicare reported H1 FY27 consolidated EBITDA of Rs 33.298 crore, up 69.81% year on year.
- Anondita Medicare's H1 FY27 consolidated EBITDA margin increased 903 basis points to 45.28%.
- Anondita Medicare's H1 FY27 consolidated revenue from operations rose 35.94% to Rs 73.5417 crore.
- Anondita Medicare's FY26 capital work-in-progress was Rs 41.495 crore, up from Rs 6.4961 crore in FY25.
powered by IRIS

Anondita Medicare Limited reported consolidated earnings before interest, tax, depreciation and amortisation (EBITDA) of Rs 33.298 crore in H1 FY27, up 69.81% from H1 FY26, as its EBITDA margin increased 903 basis points to 45.28%. Revenue from operations rose 35.94% to Rs 73.5417 crore, meaning operating profit grew faster than sales.
Know Anondita Medicare inside out
Results, valuation, peers and who's buying, in one view.
How fast did Anondita Medicare's consolidated earnings grow in H1 FY27?
Anondita Medicare's consolidated revenue from operations rose to Rs 73.5417 crore in H1 FY27 from Rs 54.097 crore in H1 FY26, a 35.94% increase. Total revenue, which includes other income, increased 36.04% to Rs 74.1465 crore from Rs 54.5048 crore over the same period.
Net profit reached Rs 22.006 crore in H1 FY27, up 69.04% from Rs 13.0179 crore a year earlier. Profit before tax increased 69.50% to Rs 29.4537 crore from Rs 17.377 crore, while diluted earnings per share (EPS) rose 29.52% to Rs 11.76 from Rs 9.08.
The H1 FY27 performance followed a higher-revenue FY26. Consolidated revenue from operations was Rs 137.4157 crore in FY26 versus Rs 76.9907 crore in FY25, a stated increase of 78%, while EBITDA rose to Rs 51.5085 crore from Rs 25.791 crore and the EBITDA margin increased 398 basis points to 37.48%.
What changed Anondita Medicare's operating margin in H1 FY27?
Anondita Medicare's reported EBITDA margin rose to 45.28% in H1 FY27 from 36.25% in H1 FY26, and net profit margin increased 586 basis points to 29.92% from 24.06%. Those wider reported margins accompanied EBITDA growth of 69.81% and net-profit growth of 69.04%, compared with 35.94% revenue growth.
Total expenses were Rs 40.8485 crore in H1 FY27, compared with Rs 34.8956 crore in H1 FY26. Materials consumed increased to Rs 27.7547 crore from Rs 23.5322 crore, while purchases of stock-in-trade rose to Rs 12.9526 crore from Rs 1.6493 crore.
The income statement recorded a negative inventory change of Rs 12.7767 crore in H1 FY27, compared with negative Rs 79.18 lakh a year earlier. Employee-benefit expense increased to Rs 4.6146 crore from Rs 3.481 crore, and other expenses rose to Rs 8.3033 crore from Rs 7.0249 crore; the presentation provides no separate management explanation for the margin movement.
Depreciation and amortisation rose to Rs 1.4215 crore from Rs 40.87 lakh, while finance costs increased to Rs 2.4228 crore from Rs 1.8235 crore. Current tax was Rs 6.9983 crore and deferred tax was Rs 44.93 lakh in H1 FY27, compared with Rs 4.2042 crore and Rs 15.49 lakh, respectively, in H1 FY26.
How did Anondita Medicare's consolidated results compare with standalone performance?
Anondita Medicare reported consolidated H1 FY27 revenue of Rs 73.5417 crore, above standalone revenue of Rs 57.8631 crore, while consolidated EBITDA of Rs 33.298 crore exceeded standalone EBITDA of Rs 24.8425 crore. The respective EBITDA margins were 45.28% and 42.93%.
Standalone revenue from operations increased 21.43% from Rs 47.6506 crore in H1 FY26 to Rs 57.8631 crore in H1 FY27. Standalone EBITDA rose 41.63% from Rs 17.5407 crore to Rs 24.8425 crore, and the standalone EBITDA margin increased 612 basis points from 36.81%.
The consolidated accounts include subsidiary Anondita Pharma and Latex Limited, identified in the presentation as formerly M/s Anondita Healthcare and Rubber Products India Limited from April 1, 2024. Consolidated H1 FY27 net profit was Rs 22.006 crore against standalone net profit of Rs 15.7925 crore, with net-profit margins of 29.92% and 27.29%, respectively.
Got a follow-up? Ask IRIS
What changed in Anondita Medicare's consolidated balance sheet?
Anondita Medicare's consolidated balance-sheet total increased to Rs 184.8312 crore in FY26 from Rs 76.8913 crore in FY25. Shareholders' funds rose to Rs 131.2692 crore from Rs 38.2788 crore, including reserves and surplus of Rs 111.1492 crore compared with Rs 23.8036 crore.
Non-current assets increased to Rs 86.3103 crore in FY26 from Rs 22.754 crore in FY25. Fixed assets rose to Rs 39.0976 crore from Rs 12.3704 crore, while capital work-in-progress increased to Rs 41.495 crore from Rs 6.4961 crore.
Current operating assets also increased in FY26. Inventories were Rs 20.7501 crore versus Rs 13.4986 crore, trade receivables were Rs 51.8567 crore versus Rs 26.7533 crore, and cash and cash equivalents rose to Rs 9.6519 crore from Rs 42.19 lakh.
Long-term borrowings increased to Rs 23.8703 crore in FY26 from Rs 11.9076 crore in FY25, whereas short-term borrowings fell to Rs 9.7312 crore from Rs 15.4834 crore. Total current liabilities were Rs 27.5785 crore compared with Rs 26.521 crore, while trade payables rose to Rs 8.0279 crore from Rs 3.8153 crore.
What expansion plans does Anondita Medicare disclose?
Anondita Medicare identifies domestic government procurement, African healthcare markets, Brazil's government healthcare procurement market, and export opportunities in Uzbekistan, Nepal, Kenya, Cuba and the United Arab Emirates. Its proposed portfolio additions are gynecological gloves, antimicrobial products and micro-optio medical gloves.
The presentation lists total condom capacity of 1,360 million units, comprising 1,119 million male condoms, including 250 million units of work in progress, and 241 million female condoms described as work in progress. Management also presents projected revenue above Rs 1,000 crore, without stating a target year, investment amount or commissioning schedule.
For female condoms, the presentation estimates potential global demand of 2 billion to 5 billion pieces annually and commercial or public-procurement demand of 700 million to 1.5 billion pieces. It estimates Cupid Limited's market share at 20% to 30% and notes that demand depends on donor funding and government procurement cycles.
Conclusion
Anondita Medicare's H1 FY27 figures show profit growth outpacing revenue growth, with consolidated EBITDA rising 69.81% to Rs 33.298 crore and net profit increasing 69.04% to Rs 22.006 crore. The FY26 balance sheet also recorded increases in fixed assets, capital work-in-progress, inventories and trade receivables alongside higher shareholders' funds.
The next disclosed items to watch are execution of the government-procurement, export and product-expansion plans, together with the Rs 41.495 crore of FY26 capital work-in-progress. Management's presentation cites projected revenue above Rs 1,000 crore, but does not disclose timing, operating milestones or investment requirements for that projection.


